Scientist, Custom Reagents B2S Life Sciences Franklin, Indiana
Description: Presently, CoA reporting of AAV serotype characterization, by non-GMP and GMP manufacturers, varies from genome/mL to information on capsid titer (cp or vp/mL); However, from a critical reagent standpoint, the total protein and capsid titer information are highly important for conjugation efficiency. Without recognized analytical methods and lot release criteria, what approach is optimal for characterizing raw material, conjugated product characterization, and assessment of lot-to-lot variability and lot release?
Learning Objectives:
Characterization of AAV starting material
Set up and optimal conditions for NHS-chemistry based AAV conjugation
Minimizing factors that can negatively impact lot-to-lot inconsistencies
